Hyperthermic Intravesical Chemotherapy Shed New Light on Therapy for NMIBC: A Meta-Analysis

Gang Zhao

doi:10.62051/4s6rzk59

Authors

Gang Zhao

DOI:

https://doi.org/10.62051/4s6rzk59

Keywords:

NMIBC; Bladder Cancer; BCG; Hyperthermic Intravesical Chemotherapy, Chemotherapy.

Abstract

Background: Non-muscle-invasive bladder cancer accounts for the 75% of bladder cancers but with limited kinds of therapies, especially in the situation that the shortage and high failure rate of intravesical bacillus Calmette-Guérin. There is some evidence that hyperthermic intravesical chemotherapy could enhance the effect of normal intravesical chemotherapy and may be the alternative. Method: To verify the effect of hyperthermic intravesical chemotherapy, we searched three databases including PubMed (Medline), Embase, and Cochrane Library for related studies. The main outcome were the OR (odds ratio) and the survival data. The quality of studies was evaluated by two authors independently using Jadad Scale for prospective studies and Newcastle-Ottawa Scale (NOS) for retrospective studies. Result: In total, 1,900 patients were included in the quantitative evaluation. The meta-analysis demonstrated significant difference in recurrence rate (OR = 0.42, 95%CI = 0.25-0.72, p=0.0015) and RFS (HR = 0.69, 95%CI = 0.54-0.88, p=0.0029) between hyperthermic intravesical chemotherapy with control groups (intravesical bacillus Calmette-Guérin and normal intravesical chemotherapy) but no obvious advantage in OS (HR = 0.84, 95%CI = 0.59-1.19, p=0.7805) and PFS (HR = 0.51, 95%CI = 0.06-4.08, p=0.5285). We separately use way of heat, control therapy, solvent, country and study type to conduct the subgroup analysis for recurrence rate and RFS. Conclusion: Hyperthermic intravesical chemotherapy can enhance the effect of normal intravesical chemotherapy and act as the alternative for intravesical bacillus Calmette-Guérin, and more studies are needed for further analyses.

Downloads

Download data is not yet available.

References

Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022; 81 (1): 75 - 94. Epub 2021/09/14. doi: 10.1016/j.eururo.2021.08.010. PubMed PMID: 34511303.

Compérat E, Larré S, Roupret M, Neuzillet Y, Pignot G, Quintens H, et al. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Archiv: an international journal of pathology. 2015; 466 (5): 589 - 94. Epub 2015/02/24. doi: 10.1007/s00428 - 015 - 1739 - 2. PubMed PMID: 25697540.

Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol. 2016; 69 (1): 60 - 9. Epub 2015/07/27. doi: 10.1016/j.eururo.2015.06.045. PubMed PMID: 26210894.

Koch GE, Smelser WW, Chang SS. Side Effects of Intravesical BCG and Chemotherapy for Bladder Cancer: What They Are and How to Manage Them. Urology. 2021; 149: 11 - 20. Epub 2020/11/13. doi: 10.1016/j.urology.2020.10.039. PubMed PMID: 33181123.

Arends TJ, van der Heijden AG, Witjes JA. Combined chemo hyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. J Urol. 2014; 192 (3): 708 - 13. Epub 2014/04/08. doi: 10.1016/j.juro.2014.03.101. PubMed PMID: 24704017.

Lunglmayr G, Czech K, Zekert F, Kellner G. Bladder hyperthermia in the treatment of vesical papillomatosis. International urology and nephrology. 1973; 5 (1): 75 - 84. Epub 1973/01/01. doi: 10.1007/bf02081753. PubMed PMID: 4203803.

Colombo R, Lev A, Da Pozzo LF, Freschi M, Gallus G, Rigatti P. A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment. J Urol. 1995; 153 (3 Pt 2): 959 - 63. Epub 1995/03/01. PubMed PMID: 7853583.

Gofrit ON, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, et al. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology. 2004; 63 (3): 466 - 71. Epub 2004/03/19. doi: 10.1016/j.urology.2003.10.036. PubMed PMID: 15028439.

Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evidence-based mental health. 2019; 22 (4): 153 - 60. Epub 2019/09/30. doi: 10.1136/ebmental-2019 - 300117. PubMed PMID: 31563865.

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8: 16. Epub 2007/06/09. doi: 10.1186/1745 - 6215 - 8 - 16. PubMed PMID: 17555582; PubMed Central PMCID: PMCPMC1920534.

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50 (4): 1088 - 101. Epub 1994/12/01. PubMed PMID: 7786990.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed). 1997; 315 (7109): 629 - 34. Epub 1997/10/06. doi: 10.1136/bmj.315.7109.629. PubMed PMID: 9310563; PubMed Central PMCID: PMCPMC2127453.

Naselli A, Hurle R, Paparella S, Buffi NM, Lughezzani G, Lista G, et al. Role of Restaging Transurethral Resection for T1 non-muscle invasive Bladder Cancer: A Systematic Review and Meta-analysis. European urology focus. 2018; 4 (4): 558 - 67. Epub 2017/07/30. doi: 10.1016/j.euf.2016.12.011. PubMed PMID: 28753839.

Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, et al. Bladder cancer. Lancet (London, England). 2016;388(10061):2796-810. Epub 2016/06/28. doi: 10.1016/s0140-6736 (16) 30512 - 8. PubMed PMID: 27345655.

Deininger S, Törzsök P, Mitterberger M, Pallauf M, Oswald D, Deininger C, et al. From Interferon to Checkpoint Inhibition Therapy-A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC). Cancers. 2022; 14 (3). Epub 2022/02/16. doi: 10.3390/cancers14030694. PubMed PMID: 35158964; PubMed Central PMCID: PMCPMC8833656.

Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009; 56 (2): 247 - 56. Epub 2009/05/05. doi: 10.1016/j.eururo.2009.04.038. PubMed PMID: 19409692.

Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003; 169 (1): 90 - 5. Epub 2002/12/13. doi: 10.1016/s0022-5347 (05) 64043 - 8. PubMed PMID: 12478111.

Song CW. Effect of hyperthermia on vascular functions of normal tissues and experimental tumors; brief communication. Journal of the National Cancer Institute. 1978; 60 (3): 711 - 3. Epub 1978/03/01. doi: 10.1093/jnci/60.3.711. PubMed PMID: 625073.

Lefor AT, Makohon S, Ackerman NB. The effects of hyperthermia on vascular permeability in experimental liver metastasis. Journal of surgical oncology. 1985; 28 (4): 297 - 300. Epub 1985/04/01. doi: 10.1002/jso.2930280412. PubMed PMID: 3982038.

Kampinga HH. Cell biological effects of hyperthermia alone or combined with radiation or drugs: a short introduction to newcomers in the field. Int J Hyperthermia. 2006; 22 (3): 191 - 6. Epub 2006/06/07. doi: 10.1080/02656730500532028. PubMed PMID: 16754338.

Milani V, Noessner E, Ghose S, Kuppner M, Ahrens B, Scharner A, et al. Heat shock protein 70: role in antigen presentation and immune stimulation. Int J Hyperthermia. 2002; 18 (6): 563 - 75. Epub 2003/01/23. doi: 10.1080/02656730210166140. PubMed PMID: 12537755.

Brace CL. Radiofrequency and microwave ablation of the liver, lung, kidney, and bone: what are the differences? Current problems in diagnostic radiology. 2009; 38 (3): 135 - 43. Epub 2009/03/21. doi: 10.1067/j.cpradiol.2007.10.001. PubMed PMID: 19298912; PubMed Central PMCID: PMCPMC2941203.

Sousa A, Inman BA, Piñeiro I, Monserrat V, Pérez A, Aparici V, et al. A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer. Int J Hyperthermia. 2014; 30 (3): 166 - 70. Epub 2014/04/05. doi: 10.3109/02656736.2014.900194. PubMed PMID: 24697672.

Tan WS, Kelly JD. Intravesical device-assisted therapies for non-muscle-invasive bladder cancer. Nature reviews Urology. 2018; 15 (11): 667 - 85. Epub 2018/09/27. doi: 10.1038/s41585 – 018 – 0092 - z. PubMed PMID: 30254383.

Soria F, Milla P, Fiorito C, Pisano F, Sogni F, Di Marco M, et al. Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I-II study. World J Urol. 2016; 34 (2): 189 - 95. Epub 2015/06/01. doi: 10.1007/s00345 - 015 - 1595 - 3. PubMed PMID: 26026818.

Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004; 171 (6 Pt 1): 2186 - 90, quiz 435. Epub 2004/05/06. doi: 10.1097/01.ju.0000125486. 92260. b2. PubMed PMID: 15126782.

Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L, et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28 (4): 543 - 8. Epub 2009/10/21. doi: 10.1200/jco.2008.20.8199. PubMed PMID: 19841330.

Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood DP, Jr., et al. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. Jama. 2018; 319 (18): 1880 - 8. Epub 2018/05/26. doi: 10.1001/jama.2018.4657. PubMed PMID: 29801011; PubMed Central PMCID: PMCPMC6583489 ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Lerner reports receipt of personal fees for advisory board membership from BioCancell, Incyte, Nucleix, and UroGen and for consultancy from Vaxiion and clinical trial grants from UroGen, Endo, FKD, Viventia, JBL, and Roche/Genentech. Dr Koppie reports receipt of personal fees from Convergent Genomics. Dr Karsh reports receipt of personal fees for consulting and/or speaking and/or research funding to his institution from Astellas, Bayer, Janssen, Sanofi, Spectrum, Precision Biopsy, 3D Biopsy, Augmenix, Dendreon, Pfizer, Abbvie, Myriad Genetics, AstraZeneca, Vaxiion, and Arivan Research. No other disclosures were reported.

Westra A, Dewey WC. Variation in sensitivity to heat shock during the cell-cycle of Chinese hamster cells in vitro. International journal of radiation biology and related studies in physics, chemistry, and medicine. 1971; 19 (5): 467 - 77. Epub 1971/01/01. doi: 10.1080/09553007114550601. PubMed PMID: 5314347.

Cavaliere R, Ciocatto EC, Giovanella BC, Heidelberger C, Johnson RO, Margottini M, et al. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer. 1967; 20 (9): 1351-81. Epub 1967/09/01. doi: 10.1002/1097-0142 (196709)20: 9<1351: aid-cncr2820200902>3.0.co; 2-#. PubMed PMID: 4292219.

van Valenberg FJP, van der Heijden AG, Lammers RJM, Falke J, Arends TJH, Oosterwijk E, et al. Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue. Int J Hyperthermia. 2018; 34 (7): 988 - 93. Epub 2017/12/02. doi: 10.1080/02656736.2017.1406618. PubMed PMID: 29191126.